Home Stock

Stock Research: Santen Pharmaceutical

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Santen Pharmaceutical

TYO:4536 JP3336000009
46
  • Value
    48
  • Growth
    25
  • Safety
    Safety
    63
  • Combined
    31
  • Sentiment
    71
  • 360° View
    360° View
    46
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company focused on the research, development, manufacturing, and sales of pharmaceutical products. It operates in medical pharmaceutical, OTC drugs, medical devices, and other businesses, including the cleaning business. The company operates in Japan, Europe, Asia, and North America markets. In the last fiscal year, the company had 3849 employees, a market cap of $3814 million, profits of $1141 million, and revenue of $2001 million.

more

ANALYSIS: With an Obermatt 360° View of 46 (better than 46% compared with alternatives), overall professional sentiment and financial characteristics for the stock Santen Pharmaceutical are below the industry average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Santen Pharmaceutical. The consolidated Sentiment Rank has a good rank of 71, which means that professional investors are more optimistic about the stock than for 71% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 63 or better than 63% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 48, meaning that the share price of Santen Pharmaceutical is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 25. ...read more

more
Strongest Rank Revenue Growth
Weakest Rank Pro Holdings
Country Japan
Industry Pharmaceuticals
Size Large
Website santen.com
Index
Santen Pharmaceutical stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 19-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
48 72 70 77
Growth
25 20 51 43
Safety
Safety
63 61 80 84
Sentiment
71 58 70 27
360° View
360° View
46 55 94 71
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
57 65 39 31
Opinions Change
50 59 82 50
Pro Holdings
n/a 40 100 37
Market Pulse
15 56 26 47
Sentiment
71 58 70 27
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
48 72 70 77
Growth
25 20 51 43
Safety Safety
63 61 80 84
Combined
31 50 90 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
50 63 62 59
Price vs. Earnings (P/E)
47 76 63 78
Price vs. Book (P/B)
39 45 56 67
Dividend Yield
81 72 76 88
Value
48 72 70 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
1 4 8 16
Profit Growth
39 58 94 96
Capital Growth
62 23 23 43
Stock Returns
63 46 79 37
Growth
25 20 51 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
81 54 63 74
Refinancing
26 44 63 61
Liquidity
69 64 76 84
Safety Safety
63 61 80 84

Similar Stocks

Discover high‑ranked alternatives to Santen Pharmaceutical and broaden your portfolio horizons.

Inpex

TYO:1605
Country: Japan
Industry: Oil & Gas Production
Size: X-Large
Full Stock Analysis

Daiwa House

TYO:1925
Country: Japan
Industry: Electric Utilities
Size: XX-Large
Full Stock Analysis

Kinden

TYO:1944
Country: Japan
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

NGK Insulators

TYO:5333
Country: Japan
Industry: Industrial Machinery
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

The value case is weak (expensive and low Growth Rank), but sentiment is strong and financing is safe. This scenario may indicate future growth not yet in current financials. This is a speculative choice for investors with a high-risk appetite who are betting on the positive sentiment and safe financing to sustain a long-term turnaround.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews